Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF for Challenging Macular Holes
NCT06115005Phase 2Unknown
- Sponsor
- Minia University
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PRGF-Endoret in macular hole, sponsored by Minia University. Primary endpoint: Number of participants that revealed closure of challenging macular holes at 6 months. Status: unknown.
02
Drugs
PRGF-Endoret
03
Conditions
macular hole
Beyond the preview
Go deeper on NCT06115005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115005.